Rhythm Biosciences Limited (ASX: RHY) has confirmed that the antibodies for the first two of four adjunct biomarkers have been successfully technically validated, stabilised and proven to be re-produceable.
CEO, Glenn Gilbert said the two adjunct biomarkers, along with the company’s key lead biomarker make up the majority of the principal ingredients needed for ColoSTAT, Rhythm’s global, low-cost, simple blood test for the detection of colorectal cancer aimed at the mass market.
Mr Gilbert said the successful technical validation for these two adjunct biomarkers, which will support the already validated key lead biomarkers, represents another step forward for the company.
Rhythm expects the final two individual biomarkers to be technically validated in the near term. Importantly, for eventual commercialisation, the ColoSTAT test will predominantly use the Company’s own version of antibodies, which are intended to be combined in the final ColoSTAT test kit.
We continue to focus on the development programme and technical validation of what we believe to be the final two adjunct biomarkers that will support the ColoSTAT test kit,” Mr Gilbert said
“We have a very focused team, and all are reinvigorated with the progress we have made over the past 6 months to advance the core technology”.
ColoSTAT is designed to be equipment agnostic and easily used by laboratories without the need for additional operator training or additional infrastructure.
The product has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.